Agree with you totally Bripoz. In the year or so before the...

Agree with you totally Bripoz. In the year or so before the latest announcements there was some spectacular news. First $27m share issue. Added such needed cornerstone investors. Meant no concerns about whether we could raise funds for a year. And no more 15% dilutions on new share issues regularly.

Then of course phase 2 results similar to Tvec. Achieved required results by half way.

Only on mobile but from memory increased mkt cap from maybe $40/50 m to around $$100. Considering what had been achieved that was not in my high range of expectations.

N
At this stage we had a drug that had pretty formidable results and money in the bank. Just no obvious interest from drug Co's. Check out announcements and articles of the time and I think Merck and Keytruda will have been mentioned in most.

Now we have an offer to do a trial with Keytruda and the market cap is I believe up 16%. Around $20m and falling??? Vla intended to run such trials but now the costs have been split. Surely this alone have saved the company and increased its value by almost $20m.

The way I see it there is no added valuation for having interest shown by owner of one of big Pd 1 drugs

Mont I hope you right about valuation not being dependent on current share price. Not 100% sure though. If results continue to go as we as they have until now and as preclinical trials suggest they may, if MC remains around $100 the re would be great incentive for Merck to make a low offer and buy the entire Co.

Only good news is the aforementioned cornerstone investors. Hopefully they would not agree.

Anyway it is how it is but I for one am bewildered - not for the first time at current share price.
All the best
Kms